The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib.
De Castro Carpeño, J
Krebs, Matthew G
AffiliationQuantitative Clinical Pharmacology, AstraZeneca, Waltham, MA, USA
MetadataShow full item record
AbstractWe investigated the effects of a strong CYP3A4 inhibitor (itraconazole) or inducer (rifampicin) on the pharmacokinetics of the epidermal growth factor receptor kinase inhibitor osimertinib, in patients with advanced non-small cell lung cancer in two phase I, open-label, two-part clinical studies. Part one of both studies is reported.
CitationThe effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib. 2018, Br J Clin Pharmacol
JournalBritish Journal of Clinical Pharmacology